30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Fidia Pharma USA Launches NuDYN Acellular Injectable Allograft -

Fidia entered the regenerative medicine segment with U.S. launch of NuDYN™ acellular amnion-derived injectable allograft. The shelf-stable, flowable allograft is the first product in the company's new orthobiologic portfolio, and complements Fidia's current hyaluronic acid-based HYALGAN® and HYMOVIS® products, which are used to treat osteoarthritis knee pain. In the U.S., Fidia seeks to diversity into new, emerging product categories to serve patients who seek non-surgical solutions. NuDYN does not require any reconstitution. As a true acellular amnion-derived allograft without any chorion, the product is non-immunogenic. Third-party CLIA-certified labs conduct serological and endotoxin testing that exceed FDA requirements to ensure the safety and quality of this product. (Fidia Pharma USA Inc., 3/12/19)